Prevalence of metabolic syndrome among patients with schizophrenia in Japan

Schizophrenia Research

Volumn 123, Issue 2-3, 2010, Pages 244-250

  Sugawara, Norio ^a   Yasui Furukori, Norio ^b   Sato, Yasushi ^a   Umeda, Takashi ^b   Kishida, Ikuko ^c,d   Yamashita, Hakuei ^e,f   Saito, Manabu ^b   Furukori, Hanako ^g   Nakagami, Taku ^h   Hatakeyama, Mitsunori ⁱ   Nakaji, Shigeyuki ^b   Kaneko, Sunao ^b  

^a Hirosaki Aiseikai Hospital   (Japan)

^b HIROSAKI UNIVERSITY   (Japan)

^c Fujisawa City Hospital   (Japan)

^d YOKOHAMA CITY UNIVERSITY   (Japan)

^e Moro Hospital   (Japan)

^f SAITAMA MEDICAL UNIVERSITY   (Japan)

^g Kuroishi City Hospital   (Japan)

^h Odate Municipal Hospital   (Japan)

ⁱ Department of Psychiatry   (Japan)

Author keywords

Japanese; Metabolic syndrome; Prevalence; Schizophrenia

Indexed keywords

ADULT; AGE DISTRIBUTION; ARTICLE; BODY MASS; CONTROLLED STUDY; FEMALE; HOSPITAL ADMISSION; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PATIENT MONITORING; PREVALENCE; PRIORITY JOURNAL; RISK REDUCTION; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SEX DIFFERENCE;

ADULT; AGE FACTORS; AGED; BODY MASS INDEX; COMORBIDITY; CROSS-SECTIONAL STUDIES; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; FEMALE; HUMANS; JAPAN; LOGISTIC MODELS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PREVALENCE; PSYCHOTIC DISORDERS; RISK FACTORS; SCHIZOPHRENIA;

EID: 77957912331     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2010.08.030     Document Type: Article

References (41)

1. Alberti K.G., Zimmet P., Shaw J. Metabolic syndrome - a new world-wide definition. A consensus statement from the International Diabetes Federation. Diabet. Med. 2006, 23:469-480.
2. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity Consensus development conference on antipsychotic drugs and obesity and diabetes. J. Clin. Psychiatry 2004, 65:267-272.
3. Arai H., Yamamoto A., Matsuzawa Y., Saito Y., Yamada N., Oikawa S., Mabuchi H., Teramoto T., Sasaki J., Nakaya N., Itakura H., Ishikawa Y., Ouchi Y., Horibe H., Shirahashi N., Kita T. Prevalence of metabolic syndrome in the general Japanese population in 2000. J. Atheroscler. Thromb. 2006, 13:202-208.
4. Basu R., Brar J.S., Chengappa K.N., John V., Parepally H., Gershon S., Schlicht P., Kupfer D.J. The prevalence of the metabolic syndrome in patients with schizoaffective disorder-bipolar subtype. Bipolar Disord. 2004, 6:314-318.
5. Bobes J., Arango C., Aranda P., Carmena R., Garcia-Garcia M., Rejas J. Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: results of the CLAMORS study. Schizophr. Res. 2007, 90:162-173.
6. Boke O., Aker S., Sarisoy G., Saricicek E.B., Sahin A.R. Prevalence of metabolic syndrome among inpatients with schizophrenia. Int. J. Psychiatry Med. 2008, 38:103-112.
7. Brown S., Inskip H., Barraclough B. Causes of the excess mortality of schizophrenia. Br. J. Psychiatry 2000, 177:212-217.
8. Cohn T., Prud'homme D., Streiner D., Kameh H., Remington G. Characterizing coronary heart disease risk in chronic schizophrenia: high prevalence of the metabolic syndrome. Can. J. Psychiatry 2004, 49:753-760.
9. De Hert M., Peuskens B., van Winkel R., Kalnicka D., Hanssens L., Van Eyck D., Wyckaert S., Peuskens J. Body weight and self-esteem in patients with schizophrenia evaluated with B-WISE. Schizophr. Res. 2006, 88:222-226.
10. Examination Committee of the Criteria for "Obesity Disease" in Japan, Japan Society for the study of Obesity New criteria for 'obesity disease' in Japan. Circ. J. 2002, 66:987-992.
11. Examination Committee of the Criteria for Metabolic Syndrome in Japan Definition and criteria of the metabolic syndrome in Japan. Jpn Intern. Med. 2005, 94:188-201. (Japanese).
12. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults Executive summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001, 285:2486-2497.
13. Fernandez-Egea E., Bernardo M., Donner T., Conget I., Parellada E., Justicia A., Esmatjes E., Garcia-Rizo C., Kirkpatrick B. Metabolic profile of antipsychotic-naive individuals with non-affective psychosis. Br. J. Psychiatry 2009, 194:434-438.
14. Ford E.S., Giles W.H., Dietz W.H. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002, 287:356-359.
15. Grundy S.M. Hypertriglyceridemia, insulin resistance, and the metabolic syndrome. Am. J. Cardiol. 1999, 83:25F-29F.
16. Grundy S.M., Cleeman J.I., Daniels S.R., Donato K.A., Eckel R.H., Franklin B.A., Gordon D.J., Krauss R.M., Savage P.J., Smith S.C., Spertus J.A., Costa F. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005, 112:2735-2752.
17. Hanley A.J., Karter A.J., Williams K., Festa A., D'Agostino R.B., Wagenknecht L.E., Haffner S.M. Prediction of type 2 diabetes mellitus with alternative definitions of the metabolic syndrome: the Insulin Resistance Atherosclerosis Study. Circulation 2005, 112:3713-3721.
18. Hsieh S.D., Yoshinaga H., Muto T. Waist-to-height ratio, a simple and practical index for assessing central fat distribution and metabolic risk in Japanese men and women. Int. J. Obes. 2003, 27:610-616.
19. Huang M.C., Lu M.L., Tsai C.J., Chen P.Y., Chiu C.C., Jian D.L., Lin K.M., Chen C.H. Prevalence of metabolic syndrome among patients with schizophrenia or schizoaffective disorder in Taiwan. Acta Psychiatr. Scand. 2009, 120:274-280.
20. International Diabetes Federation The IDF consensus worldwide definition of the metabolic syndrome Available from, Accessed 1 May 2007. http://www.idf.org/.
21. Isomaa B., Almgren P., Tuomi T., Forsen B., Lahti K., Nissen M., Taskinen M.R., Groop L. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diab. Care 2001, 24:683-689.
22. Kaneda Y., Fujii A., Ohmori T. The hypothalamic-pituitary-adrenal axis in chronic schizophrenic patients long-term treated with neuroleptics. Prog. Neuropsychopharmacol. Biol. Psychiatry 2002, 26:935-938.
23. Lakka H.M., Laaksonen D.E., Lakka T.A., Niskanen L.K., Kumpusalo E., Tuomilehto J., Salonen J.T. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002, 288:2709-2716.
24. Lear S.A., Toma M., Birmingham C.L., Frohlich J.J. Modification of the relationship between simple anthropometric indices and risk factors by ethnic background. Metabolism 2003, 52:1295-1301.
25. Lee J.S., Kawakubo K., Mori K., Akabayashi A. Effective cut-off values of waist circumference to detect the clustering of cardiovascular risk factors of metabolic syndrome in Japanese men and women. Diab. Vasc. Dis. Res. 2007, 4:340-345.
26. Lyketsos C.G., Dunn G., Kaminsky M.J., Breakey W.R. Medical comorbidity in psychiatric inpatients: relation to clinical outcomes and hospital length of stay. Psychosomatics 2002, 43:24-30.
27. McEvoy J.P., Meyer J.M., Goff D.C., Nasrallah H.A., Davis S.M., Sullivan L., Meltzer H.Y., Hsiao J., Scott Stroup T., Lieberman J.A. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr. Res. 2005, 80:19-32.
28. Meyer J.M., Nasrallah H.A., McEvoy J.P., Goff D.C., Davis S.M., Chakos M., Patel J.K., Keefe R.S., Stroup T.S., Lieberman J.A. The Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE) Schizophrenia Trial: clinical comparison of subgroups with and without the metabolic syndrome. Schizophr. Res. 2005, 80:9-18.
29. Ninomiya T., Kubo M., Doi Y., Yonemoto K., Tanizaki Y., Rahman M., Arima H., Tsuryuya K., Iida M., Kiyohara Y. Impact of metabolic syndrome on the development of cardiovascular disease in a general Japanese population: the Hisayama study. Stroke 2007, 38:2063-2069.
30. Osby U., Correia N., Brandt L., Ekbom A., Sparen P. Mortality and causes of death in schizophrenia in Stockholm county, Sweden. Schizophr. Res. 2000, 45:21-28.
31. Phillips L.K., Prins J.B. The link between abdominal obesity and the metabolic syndrome. Curr. Hypertens. Rep. 2008, 10:156-164.
32. Ryan M.C., Thakore J.H. Physical consequences of schizophrenia and its treatment: the metabolic syndrome. Life Sci. 2002, 71:239-257.
33. Ryan M.C., Collins P., Thakore J.H. Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am. J. Psychiatry 2003, 160:284-289.
34. Saddichha S., Manjunatha N., Ameen S., Akhtar S. Metabolic syndrome in first episode schizophrenia - a randomized double-blind controlled, short-term prospective study. Schizophr. Res. 2008, 101:266-272.
35. Sicras-Mainar A., Blanca-Tamayo M., Rejas-Gutierrez J., Navarro-Artieda R. Metabolic syndrome in outpatients receiving antipsychotic therapy in routine clinical practice: a cross-sectional assessment of a primary health care database. Eur. Psychiatry 2008, 23:100-108.
36. Srisurapanont M., Likhitsathian S., Boonyanaruthee V., Charnsilp C., Jarusuraisin N. Metabolic syndrome in Thai schizophrenic patients: a naturalistic one-year follow-up study. BMC Psychiatry 2007, 23:7-14.
37. Suvisaari J.M., Saarni S.I., Perala J., Suvisaari J.V., Harkanen T., Lonnqvist J., Reunanen A. Metabolic syndrome among persons with schizophrenia and other psychotic disorders in a general population survey. J. Clin. Psychiatry 2007, 68:1045-1055.
38. Tan C.E., Ma S., Wai D., Chew S.K., Tai E.S. Can we apply the National Cholesterol Education Program Adult Treatment Panel definition of the metabolic syndrome to Asians?. Diab. Care 2004, 27:1182-1186.
39. Thakore J.H., Mann J.N., Vlahos I., Martin A., Reznek R. Increased visceral fat distribution in drug-naive and drug-free patients with schizophrenia. Int. J. Obes. Relat. Metab. Disord. 2002, 26:137-141.
40. Weiden P.J., Mackell J.A., McDonnell D.D. Obesity as a risk factor for antipsychotic noncompliance. Schizophr. Res. 2004, 66:51-57.
41. Wilson P.W., D'Agostino R.B., Parise H., Sullivan L., Meigs J.B. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation 2005, 112:3066-3072.